Amycretin vs CagriSema: Unimolecular vs Combination GLP-1/Amylin Therapy

Introduction#

Amycretin and CagriSema represent two approaches to the same therapeutic concept: combining GLP-1 receptor agonism with amylin receptor agonism for obesity and diabetes treatment. Both are Novo Nordisk programs, but they employ fundamentally different molecular strategies. CagriSema is a fixed-ratio combination of two separate peptides (cagrilintide + semaglutide) delivered as a single weekly injection. Amycretin is a unimolecular dual agonist -- a single molecule that activates both GLP-1 and amylin receptors -- available in both injectable and oral formulations.

This intra-company comparison is particularly interesting because it reveals Novo Nordisk's multi-pronged strategy for next-generation obesity therapy. CagriSema leverages two individually validated components and is further along in development (phase 3 completed). Amycretin offers the simplicity of a single molecule and the transformative potential of oral dual agonist therapy, but with earlier-stage evidence.

Mechanism of Action Comparison#

Amycretin#

Amycretin is the first unimolecular dual GLP-1 and amylin receptor agonist. A single molecular entity simultaneously activates both the GLP-1 receptor and the amylin receptor (calcitonin receptor complex), combining two complementary satiety and metabolic pathways:

• GLP-1 receptor activation: Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction through hypothalamic signaling
• Amylin receptor activation: Additional satiety signaling through the area postrema, complementary gastric emptying delay, and glucagon suppression through a distinct mechanism

The unimolecular design means both receptor activations occur at a fixed ratio determined by the molecular structure. Amycretin has been developed in both subcutaneous (once weekly) and oral (daily) formulations.

CagriSema#

CagriSema is a fixed-ratio combination of two distinct peptide molecules in a single injection device:

• Cagrilintide: A long-acting amylin analog with a ~7-day half-life achieved through fatty acid acylation. Activates amylin receptors for satiety, gastric emptying delay, and glucagon suppression
• Semaglutide: The selective GLP-1 receptor agonist with a ~7-day half-life. The same molecule as Ozempic/Wegovy

The combination approach has the advantage of using two individually optimized and validated components. Each component has demonstrated independent efficacy, and the combination produces additive effects on weight loss and glycemic control.

Mechanistic Comparison#

Dosing Comparison#

Amycretin Dosing#

Amycretin dosing is investigational:

• Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks
• Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1
• Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks

Phase 3 dose selection will be informed by the completed phase 2 data. Novo Nordisk plans to initiate phase 3 in 2026.

CagriSema Dosing#

CagriSema is a fixed-ratio combination in a single pen injector:

• Once-weekly subcutaneous injection containing both cagrilintide and semaglutide
• REDEFINE 1: Dose escalation to the maintenance combination dose over several weeks
• Dosing ratio: Fixed ratio optimized during the phase 2 program

Dosing Comparison Table#

Side Effects Comparison#

Amycretin Side Effects#

In the phase 1b/2a trial published in The Lancet, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. GI events were the most common adverse effects, with the vast majority being mild to moderate in severity. Both subcutaneous and oral formulations appeared safe and well tolerated. The phase 2 T2D trial similarly reported a safe and well-tolerated profile.

CagriSema Side Effects#

In REDEFINE 1, GI adverse events affected 79.6% of participants in the CagriSema group vs 39.9% in the placebo group. These included nausea, vomiting, diarrhea, constipation, and abdominal pain, and were mainly transient and mild to moderate. This high overall GI rate (while mostly mild) likely reflects the combined GI effects of activating both GLP-1 and amylin pathways simultaneously.

For context, CagriSema's GI rate was compared to its individual components: semaglutide alone and cagrilintide alone both had lower GI event rates than the combination, consistent with additive GI effects.

Safety Comparison Table#

Research Evidence Comparison#

Amycretin Research#

Amycretin has early but impressive data:

• Phase 1 (SC): Published in The Lancet (2025). Safety, tolerability, PK, and PD in people with overweight/obesity. Demonstrated proof-of-concept for the dual agonist approach
• Phase 1b/2a (SC): Up to 24% weight loss at 36 weeks with doses up to 60 mg. Weight loss trajectory was still accelerating
• Phase 1 (oral): 10.4-13.1% weight loss at 12 weeks depending on dosing regimen vs 1.2% placebo
• Phase 2 (T2D): SC amycretin showed up to 14.5% weight loss and HbA1c reductions up to 1.8% at 36 weeks. Oral amycretin showed up to 10.1% weight loss

Evidence level: Low-moderate -- early-phase data with Lancet publication, impressive trajectories, but small samples and short duration.

CagriSema Research#

CagriSema has comprehensive phase 3 evidence:

• REDEFINE 1 (obesity): Phase 3, 68 weeks, ~3,400 patients. Mean weight loss -20.4% vs -3.0% placebo. 60% achieved 20% or more, 23% achieved 30% or more. Semaglutide alone: -14.9%. Cagrilintide alone: -11.5%
• REDEFINE 2 (obesity + T2D): Phase 3, 68 weeks, ~1,200 patients. Weight loss -13.7% vs -3.4% placebo. 73.5% achieved HbA1c of 6.5% or less vs 15.9% placebo
• Publication: Both trials published simultaneously in NEJM (2025) and presented at ADA 2025

Evidence level: High -- completed phase 3 program with dual NEJM publications and >4,600 total participants.

Key Differences Summary#

• Molecular design: Amycretin is a single molecule activating two receptors. CagriSema combines two separate validated molecules. The unimolecular approach is simpler but less flexible; the combination allows independent dose optimization.
• Oral formulation: Amycretin's most transformative advantage. Oral amycretin showed 13.1% weight loss at 12 weeks, offering the possibility of an oral dual GLP-1/amylin agonist. CagriSema's antibody-free peptide combination is injectable only.
• Weight loss data: Subcutaneous amycretin achieved 24% at 36 weeks (phase 1b/2a) -- if this holds in phase 3, it would exceed CagriSema's 20.4% at 68 weeks (phase 3). However, phase 2 results frequently attenuate in larger trials.
• Evidence maturity: CagriSema has completed phase 3 with NEJM publications and >4,600 patients. Amycretin has early-phase data with phase 3 planned for 2026.
• Component validation: CagriSema benefits from each component (semaglutide, cagrilintide) having independent extensive clinical data. Amycretin has no separate component validation since it is a single molecule.
• Developer strategy: Both are Novo Nordisk programs, suggesting the company views them as complementary rather than competing -- CagriSema as the nearer-term injectable option, amycretin as the longer-term oral strategy.

Conclusion#

Amycretin and CagriSema illustrate two philosophies for combining GLP-1 and amylin receptor activation. CagriSema takes the combination approach -- pairing two proven molecules (semaglutide and cagrilintide) in a single injection that produced 20.4% weight loss in phase 3, with 60% of patients losing 20% or more. Its advantages are the strength of the evidence (dual NEJM publications, >4,600 patients) and the independent validation of each component.

Amycretin takes the unimolecular approach -- encoding both GLP-1 and amylin agonism into a single molecule. Its early data is remarkable, with up to 24% weight loss at 36 weeks subcutaneously and 13.1% at 12 weeks orally. The oral formulation is the most significant differentiator: if an oral tablet can produce weight loss comparable to injectable CagriSema, it could fundamentally change how dual pathway obesity therapy is delivered.

Both drugs are being developed by Novo Nordisk, likely reflecting a portfolio strategy: CagriSema as the first-to-market injectable combination, and amycretin as a follow-on oral option for patients who prefer pills. The company's decision to advance both programs suggests confidence that the GLP-1/amylin dual pathway represents the future of obesity pharmacotherapy, with room for multiple formulations serving different patient preferences.

For clinicians and patients, the practical timeline matters: CagriSema is closer to potential approval (phase 3 complete), while amycretin's phase 3 is planned for 2026. The oral option may ultimately be the more transformative contribution, but CagriSema will likely reach the market first.

Further Reading#

• Amycretin Overview and Research Guide
• Amycretin Side Effects
• Amycretin Dosing Protocols
• CagriSema Overview and Research Guide
• CagriSema Side Effects
• CagriSema Dosing Protocols